Video+

Alfred Kim talks about the initial promise of hydroxychloroquine for COVID-19 and why it did not stand up to later scrutiny (13:06).

In the introductory podcast for our series on repurposing rheumatology drugs for COVID-19, Jinoos Yazdany discusses the rationale behind investigating these agents and explores the role of rheumatologists in ensuring they are studied as safely and efficiently as possible (13:07).

Sangeeta Sule, from Children’s National Hospital in Washington, DC, USA, shares her experience of how the pediatric rheumatology community is adapting to the COVID-19 pandemic, including the use of telemedicine practices (9:06).

In this Medicine Matters rheumatology podcast, Editorial Board member Victoria Ruffing discusses the impact that musculoskeletal diseases can have on work, and the various recommendations and resources that can help patients to remain in the workplace.

In this Medicine Matters rheumatology podcast, Editorial Board member Victoria Ruffing discusses the causes of sleep problems in patients with rheumatic diseases, the impact these may have on symptoms and quality of life, and strategies to help patients manage their sleep.

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

In this medwireNews podcast, we talk to Editorial Board member Sangeeta Sule about how patients with juvenile arthritis transition from pediatric to adult care, the challenges associated with this transition, and how the process can be improved.

In this medwireNews podcast, Athimalaipet Ramanan outlines the importance of the SHARE recommendations for children with JIA-associated uveitis, and discusses how rheumatologists and ophthalmologists can work together.

In this medwireNews podcast, Editorial Board member Victoria Ruffing discusses how to talk to patients about biosimilar drugs, and outlines questions and concerns they may have.

Study investigator Jennifer Stinson discusses a trial assessing an online program to help teenagers with juvenile idiopathic arthritis to manage their condition.